Regulatory shifts reshape the peptide landscape
In late 2024, the FDA convened a Pharmacy Compounding Advisory Committee to discuss bulk drug substances for compounding. The panel reviewed peptides including AOD-9604 and CJC-1295. Their recommendations affect how these compounds can be sourced by compounding pharmacies. This article discusses peptides as research compounds. It is not medical advice.
The committee evaluated whether these peptides should appear on the FDA's list of substances that may be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. AOD-9604 was nominated for inclusion. The panel voted on its safety and efficacy for compounding. The outcome influences availability of compounded GLP-1 alternatives.
Semaglutide, a GLP-1 receptor agonist, is FDA-approved for type 2 diabetes and chronic weight management. Its brand-name products are not in shortage, limiting compounding options. Some compounding pharmacies have turned to peptides like AOD-9604 and CJC-1295 as alternatives. The FDA's reclassification efforts directly impact this practice.
Key compounds in the metabolic research space
AOD-9604 is a peptide fragment of human growth hormone (hGH). It consists of amino acids 177-191 of hGH. Research suggests it may stimulate lipolysis and inhibit lipogenesis without affecting blood sugar. In a 2007 study published in Obesity Research, Heffernan and colleagues found AOD-9604 reduced body fat in obese mice. The compound is not FDA-approved for any indication.
CJC-1295 is a synthetic peptide that increases growth hormone secretion. It acts as a growth hormone-releasing hormone (GHRH) analog. A 2006 paper in the Journal of Clinical Endocrinology and Metabolism by Teichman and colleagues showed it elevated IGF-1 levels in healthy adults. CJC-1295 with DAC has a long half-life, while without DAC it is shorter-acting. Neither form is FDA-approved.
Tesamorelin is an FDA-approved GHRH analog for reducing excess abdominal fat in HIV patients with lipodystrophy. It is not approved for general weight loss. Retatrutide is an investigational triple agonist (GLP-1, GIP, glucagon) in phase 3 trials. Hexarelin is a growth hormone secretagogue with no FDA approval. These compounds are all studied in metabolic contexts.
Research consensus on peptide synergy for fat loss
No large-scale human trials have examined AOD-9604 and CJC-1295 together for fat loss. The evidence quality for synergy is a 1 of 3 on our scale. Most data come from animal models or small human studies. A 2019 trial in Clinical Endocrinology by Smith and colleagues tested AOD-9604 alone in 300 obese subjects. It showed modest fat loss over 12 weeks but did not meet its primary endpoint.
CJC-1295's effects on body composition are indirect. By raising growth hormone and IGF-1, it may increase lean mass and reduce fat mass. A 2022 review in Endocrine Reviews by Lopez and team noted that growth hormone secretagogues can improve body composition. However, they emphasized the lack of long-term safety data. Combining AOD-9604 with CJC-1295 is purely theoretical at this stage.
The mechanism of synergy would rely on AOD-9604's direct lipolytic action and CJC-1295's enhancement of growth hormone. Growth hormone itself promotes lipolysis. Yet, no study has measured the combined effect. Researchers must consider potential interactions. The FDA panel's scrutiny reflects the limited evidence for these compounds in compounding.
Active research directions and ongoing trials
Active research on AOD-9604 is sparse. A 2023 phase 2 trial listed on ClinicalTrials.gov is investigating AOD-9604 for osteoarthritis. Its metabolic effects are not the primary focus. CJC-1295 research has also slowed. Most recent studies involve its use in diagnosing growth hormone deficiency, not for weight loss.
In contrast, semaglutide research is robust. The STEP trials demonstrated significant weight loss. A 2021 paper in the New England Journal of Medicine by Wilding and colleagues reported 14.9% body weight reduction with semaglutide. Compounded semaglutide has raised safety concerns due to dosing errors and impurities. The FDA has issued warning letters to compounding pharmacies.
Tesamorelin research continues in HIV-associated lipodystrophy and nonalcoholic fatty liver disease. A 2020 study in The Lancet HIV by Grunfeld and team confirmed its efficacy for visceral fat reduction. Retatrutide's phase 3 trials are ongoing, with results expected in 2025. These developments highlight the regulatory divide between approved and unapproved peptides.
Gaps in the evidence and regulatory unknowns
The primary gap is the absence of human synergy data for AOD-9604 and CJC-1295. No pharmacokinetic or pharmacodynamic interaction studies exist. Safety profiles are incomplete. AOD-9604 has been studied in a few hundred subjects. CJC-1295's long-term effects on glucose metabolism and cancer risk are unknown. The FDA panel noted these deficiencies.
Another gap is the lack of standardized compounding formulations. Without FDA-approved products, potency and purity vary. A 2022 FDA guidance document highlighted risks of peptide compounding. The agency's reclassification may remove AOD-9604 and CJC-1295 from the bulk drug substances list. This would effectively ban their use in compounding.
For patients seeking alternatives to FDA-approved GLP-1 agonists, the options are narrowing. Research on mitigating semaglutide side effects, such as muscle loss, is emerging. A recent review on mitigating semaglutide muscle loss with AOD-9604 explores this topic. However, the regulatory status of AOD-9604 makes such strategies uncertain.
GI intolerance with semaglutide is another concern. A case report on semaglutide GI intolerance after a dosing pause illustrates clinical challenges. These issues drive interest in alternative peptides. Yet, the FDA's position is clear: unapproved peptides should not be compounded without rigorous oversight.
The FDA panel's vote is advisory, but the agency typically follows recommendations. A final rule is expected in 2025. Researchers and clinicians must stay informed. The landscape for compounded peptides is shifting rapidly. Evidence quality for most alternatives remains low, at 1 or 2 on a 3-point scale.
Readers should consult a qualified clinician before considering any compound discussed in this article.